Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00024076 · ClinicalTrials.gov registry record · Phase 2

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

A Phase 2 study of Lung Cancer and Metastatic Cancer, sponsored by Jonsson Comprehensive Cancer Center.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT00024076: Completed Phase 2 study of Lung Cancer and Metastatic Cancer, sponsored by Jonsson Comprehensive Cancer Center.

NCT00024076 is a Phase 2 study of Lung Cancer and Metastatic Cancer that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 30 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00024076, a Phase 2 study of Lung Cancer and Metastatic Cancer, has completed, sponsored by Jonsson Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

Conditions Studied

Lung Cancer Metastatic Cancer Malignant Mesothelioma Thymoma and Thymic Carcinoma

Interventions

  • PROCEDURE radiofrequency ablation

Study Locations (1)

California

  • Jonsson Comprehensive Cancer Center, UCLA - Los Angeles

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2000-05
Phase Phase 2
Jonsson Comprehensive Cancer Center

321 total trials

What the finished NCT00024076 record still lists

NCT00024076 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (97% lower).

The record links to 4 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which radiofrequency ablation is the first listed.

NCT00024076 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00024076 about?

NCT00024076 is a clinical study titled "Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer". RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanc...

What is the current status of trial NCT00024076?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2000-05.

What conditions does trial NCT00024076 study?

This clinical trial studies the following conditions: Lung Cancer, Metastatic Cancer, Malignant Mesothelioma, Thymoma and Thymic Carcinoma.

What interventions are being tested in trial NCT00024076?

The interventions under investigation include: radiofrequency ablation (PROCEDURE).

Who is sponsoring clinical trial NCT00024076?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00024076 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00024076's enrollment target sits among peer trials

30 318th of 409 higher than 80 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00024076, the US trial registry maintained by the National Library of Medicine. NCT00024076 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.